Computational design of a multi-epitope-based vaccine targeting the BF.7 Omicron variant of SARS-CoV-2
Gene Reports, ISSN: 2452-0144, Vol: 36, Page: 101943
2024
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Article Description
In recent times, the SARS-CoV-2 virus has been observed to cause a serious threat to the world through its high permissive mutations by adapting itself to the host environment, which is a time to design an effective vaccine that could be able to produce immune response to fight against the virus. An Immunoinformatics approach was employed to conduct a high-throughput analysis aimed at developing a multi-epitope-based vaccine that specifically targets the BF.7 Omicron variant, which is currently a variant of concern. The essential aspect for the successful development of a vaccine lies in identifying B-cell and T-cell epitopes that exhibit both antigenic features, capable of eliciting a defensive immune response, while also possessing non-allergenic characteristics to prevent any harmful allergic reactions. These epitopes are essential for the development of vaccines because they aid in the immune system's ability to identify and attack certain infections without inducing unfavorable allergic reactions. The Docking and MD simulation studies have shown structural stability and Toll-like receptors with chosen vaccine architecture interact strongly. The in-silico immune simulation boosted the research study confirming the efficiency of the vaccination that has the potential to stimulate immunological responses by producing antibodies to not only targeting the specific VOC, BF.7 Omicron variant but also other omicron sublineages. Overall, the computational study have provided strong evidences to the designed vaccine construct which needs to be confirmed through the experiemental study.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2452014424000669; http://dx.doi.org/10.1016/j.genrep.2024.101943; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85195165099&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S2452014424000669; https://dx.doi.org/10.1016/j.genrep.2024.101943
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know